PLOD2、PRDX6在膀胱癌组织中的表达及其临床意义  

Expression of PLOD2 and PRDX6 in bladder cancer and their clinical significance

作　　者：李红净 马艳霞 郭俊花 苗艳丽 徐静[1] LI Hongjing;MA Yanxia;GUO Junhua;MIAO Yanli;XU Jing(Department of Urology,First Hospital of Handan,Hebei,056002,China;Department of Internal Medicine,First Hospital of Handan)

机构地区：[1]邯郸市第一医院泌尿外科,河北邯郸056002 [2]邯郸市第一医院内科

出　　处：《临床泌尿外科杂志》2025年第1期64-70,共7页Journal of Clinical Urology

摘　　要：目的:探讨膀胱癌组织中赖氨酸羟化酶2(procollagen-lysine 2-oxoglutarate 5-dioxygenase2,PLOD2)、过氧化物氧化还原蛋白6(peroxiredoxin-6,PRDX6)的表达水平及其临床意义。方法:选择2017年9月—2020年8月邯郸市第一医院收治的113例膀胱癌患者作为研究对象;采用实时荧光定量PCR(qRT-PCR)法检测PLOD2、PRDX6mRNA的相对表达量;采用免疫组织化学染色法测定PLOD2、PRDX6蛋白表达;膀胱癌组织中PLOD2、PRDX6表达与膀胱癌患者预后的关系采用Kaplan-Meier生存曲线分析;膀胱癌患者预后的影响因素采用Cox回归分析。结果:膀胱癌组织中PLOD2 mRNA、PRDX6 mRNA表达水平以及PLOD2、PRDX6阳性表达率均显著高于癌旁组织(P<0.05)。膀胱癌患者TNM分期为Ⅲ~Ⅳ期、肿瘤分化程度为低分化、浸润深度为肌层浸润的PLOD2、PRDX6蛋白阳性表达率显著高于TNM分期为Ⅰ~Ⅱ期、肿瘤分化程度为高、中分化、浸润深度为非肌层浸润(P<0.05)。PLOD2阳性表达患者3年无病生存率显著低于PLOD2阴性表达患者(63.64%vs85.11%,χ^(2)=7.093,P=0.008);PRDX6阳性表达患者3年无病生存率显著低于PRDX6阴性表达患者(65.08%vs82.00%,χ^(2)=4.756,P=0.029)。TNM分期为Ⅲ~Ⅳ期、肌层浸润、肿瘤低分化以及PLOD2和PRDX6阳性表达是影响膀胱癌患者预后的危险因素(P<0.05)。结论:膀胱癌组织中PLOD2、PRDX6表达异常上升,二者与TNM分期、浸润深度、肿瘤分化程度有关,可作为膀胱癌预后相关的肿瘤标志物。Objective:To investigate the expressions of procollagen-lysine 2-oxoglutarate 5-dioxygenase 2(PLOD2)and peroxiredoxin-6(PRDX6)in bladder cancer and their clinical significance.Methods:From September 2017 to August 2020,113 patients with bladder cancer admitted to our hospital were collected as the study subjects.The relative expressions of PLOD2 and PRDX6 mRNA were assayed by real-time fluorescence quantitative PCR(qRT-PCR),and immunohistochemical staining was applied to determine the expressions of PLOD2 and PRDX6 proteins.The relationship between PLOD2,PRDX6 expressions in bladder cancer tissues and the prognosis of bladder cancer patients was analyzed by Kaplan-Meier survival curve,and the prognostic factors of bladder cancer patients were analyzed by Cox regression.Results:The expression levels of PLOD2 mRNA and PRDX6 mRNA and the positive expression rates of PLOD2 and PRDX6 in bladder cancer tissues were significantly higher than those in paracancer tissues(P<0.05).The positive expression rates of PLOD2 and PRDX6 in bladder cancer patients with TNM stageⅢ-Ⅳ,low differentiation and invasion depth of muscle invasion were significantly higher than those with TNM stageⅠ-Ⅱ,high/moderate differentiation and invasion depth of non-muscle invasion(P<0.05).The 3-year disease-free survival rate of PLOD2 positive expression patients was obviously lower than that of PLOD2 negative expression patients(63.64%vs 85.11%,χ^(2)=7.093,P=0.008),and the 3-year disease-free survival rate of PRDX6 positive expression patients was obviously lower than that of PRDX6 negative expression patients(65.08%vs 82.00%,χ^(2)=4.756,P=0.029).Cox regression analysis showed that TNM stageⅢ-Ⅳ,muscular invasion,tumor low differentiation,and the positive expressions of PLOD2 and PRDX6 were the risk factors affecting the prognosis of bladder cancer patients(P<0.05).Conclusion:The abnormal increased expressions of PLOD2 and PRDX6 in bladder cancer and their relationship with TNM stage,depth of invasion and tumor differentiation can be us

关 键 词：膀胱癌 赖氨酸羟化酶2 过氧化物氧化还原蛋白6 预后 

分 类 号：R737.14[医药卫生—肿瘤]